Hot Defensive Companies To Invest In Right Now

Investors have been nervous about the stock market's nearly straight-up movement over the past several months, as stocks have been remarkably resilient even in the face of past bad news. But today's onslaught of troubling items -- ranging from slowing Chinese economic growth and a nearly 10% plunge in gold prices to the deadly explosions at the Boston Marathon -- were enough to provoke a massive sell-off on Wall Street, with the Dow Jones Industrials (DJINDICES: ^DJI  ) closing down 266 points. The S&P 500 dropped more than 2%, and the small-cap Russell 2000 Index suffered a nearly 4% decline.

Not a single Dow component managed to post even the tiniest of gains, but a couple of stocks minimized their losses. Wal-Mart (NYSE: WMT  ) finished down 0.1%, fulfilling its traditional role of holding up well as a defensive stock in light of potential threats to future economic growth. The company announced that it would boost its energy efficiency and commitment to renewable energy in an attempt to cut costs, but the discount retailer's strong performance in past recessionary times is likely the real reason behind its managing to hold up well today.

Hot Growth Stocks To Watch Right Now: Rexahn Pharmaceuticals Inc (RNN)

Rexahn Pharmaceuticals, Inc. (Rexahn) is a development-stage biopharmaceutical company. The Company focuses on the development of cures for cancer to patients worldwide. The Company�� pipeline features one drug candidate in Phase II clinical trials. The Company also has several other drug candidates in pre-clinical development. In addition, the Company has two renal cell carcinoma (CNS) candidates, Serdaxin, CNS Disorders drug for depression and neurodegenerative diseases and Zoraxel, which is a erectile dysfunction (ED) and sexual dysfunction drug that are in clinical stages and the Company is are exploring options for further development . The Company�� drug candidate, Archexin is an anticancer Akt inhibitor.

Archexin

Archexin is potent inhibitor of the Akt protein kinase (Akt) in cancer cells. Archexin has FDA orphan drug designations for five cancers (RCC, glioblastoma, and cancers of the ovary, stomach and pancreas). Multiple indications for other solid tumors can also be pursued. Archexin inhibit both activated and inactivated forms of Akt, and to reverse the drug resistance observed with the protein kinase inhibitors. Archexin is an antisense oligonucleotide (ASO) compound that is complementary to Akt mRNA, and selective for inhibiting mRNA expression and production of Akt protein. As of December 31, 2011, Archexin was in Phase II clinical trials for the treatment of pancreatic cancer with enrollment completed in September, 2011.

Serdaxin

Serdaxin is an extended release formulation of clavulanic acid, which is an ingredient present in antibiotics approved by the FDA. The Company had been developing Serdaxin for the treatment of depression and neurodegenerative disorders. From January to September, 2011, the Company conducted a randomized, double-blind, placebo-controlled study compared two doses of Serdaxin, 0.5 milligram and 5 milligram, to placebo over an eight-week treatment period for major depressive disorder (MDD) patients. As of Dec! ember 31, 2011, the Company had not made a determination of Serdaxin�� future paths or resource allocations to further develop Serdaxin to treat MDD.

Zoraxel

Zoraxel is an orally administered, on-demand tablet to treat sexual dysfunction. Zoraxel is a dual enhancer of neurotransmitters in the brain that play a key role in sexual activity phases of motivation and arousal, erection and release, and may be the ED drug to affect all three of these phases of sexual activity. As of December 31, 2011, the Company was evaluating how to proceed with the Phase IIb study of Zoraxel.

The Company�� Pre-clinical Pipeline Drug Candidates includes RX-1792, which is a small molecule anticancer EGFR inhibitor; RX-5902, which is a small molecule anticancer ribonucleic acid (RNA) helicase regulator; RX-3117, which is a Small molecule anticancer deoxyribonucleic acid (DNA) synthesis Inhibitor; RX-8243, which is a small molecule anticancer aurora kinase inhibitor; RX-0201-Nano, which is a nanoliposomal anticancer Akt inhibitor; RX-0047-Nano, which is an nanoliposomal anticancer HIF-1 alpha inhibitor and RX-21101, which is a nano-polymer Anticancer.

Advisors' Opinion:

• [By James E. Brumley]

  With just a quick glance at a chart of Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), it would be easy to conclude it's nothing but a volatile mess. When you take a step back and look at a long-term weekly chart of RNN, however, it starts to become clear that this small cap biopharma name is on the verge of a monster-sized breakout. First things first, however.

• [By James E. Brumley]

  If you were lucky enough to step into Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) when your truly suggested it was a budding buy back on December 23rd, then congratulations - you're now up a little more than 60% (assuming you bought into RNN after the break above a key resistance line on the 27th). Now get out. Instead, use your profits from the Rexahn to take on a stake in GTx, Inc. (NASDAQ:GTXI). No, GTXI may not look like much at first, but when you take a step back and look at a chart of GTx, Inc. through a longer-term lens, the upside potential becomes clear.

Hot Defensive Companies To Invest In Right Now: Boingo Wireless Inc.(WIFI)

Boingo Wireless, Inc., together with its subsidiaries, provides mobile Wi-Fi Internet solutions. The company installs, manages, and operates wireless network infrastructure to provide Wi-Fi services at its managed and operated hotspots, such as airports, hotels, coffee shops, shopping malls, arenas, stadiums, and quick service restaurants in North America, South America, Europe, the Middle East, Africa, and Asia. Its solution includes software for Wi-Fi enabled devices comprising smartphones, laptops, and tablet computers, as well as back-end system infrastructure that detects and enables access to Wi-Fi network. The company provides its solutions to individual users and partners consisting of telecom operators, network operators, cable companies, technology companies, enterprise software and services companies, and communications companies. In addition, it provides billing system and customer support services. Boingo Wireless, Inc. was founded in 2001 and is headquartered in Los Angeles, California.

Advisors' Opinion:

• [By Rich Smith]

  Boingo Wireless (NASDAQ: WIFI  ) has a new president.

  On Monday, the provider of Wi-Fi hotspots at airports, shopping malls, restaurants, and similar locations announced that it has hired away Rubicon Project�Chief Revenue Officer Nick Hulse to become its president. Reporting to CEO Dave Hagan, Hulse will be responsible for maximizing revenue at Boingo.

Hot Defensive Companies To Invest In Right Now: The Fresh Market Inc.(TFM)

The Fresh Market, Inc. operates as a specialty grocery retailer. The company offers various perishable product categories, including meat, seafood, produce, deli, bakery, floral, sushi, and prepared foods; and non-perishable product categories, such as traditional grocery and dairy products, as well as specialty foods, which include bulk, coffee and candy, and beer and wine. As of March 20, 2012, it operated 115 stores in 21 states located in the southeast, midwest, mid-Atlantic, and northeast of United States. The company was founded in 1981 and is headquartered in Greensboro, North Carolina.

Advisors' Opinion:

• [By Wallace Witkowski]

  Fresh Market Inc. (TFM) �shares rose 10% to $31.65 on moderate volume after the high-end food market posted higher-than-expected revenue for the first quarter.

• [By Steve Symington]

  Here's who it won't affect
  That said, investors absolutely�should not�assume Wal-Mart's initiative poses any realistic threat to specialty organic grocery businesses like Whole Foods (NASDAQ: WFM  ) and The Fresh Market (NASDAQ: TFM  ) , which both typically serve�very�different client bases than those to which Wal-Mart caters.

Hot Defensive Companies To Invest In Right Now: Astellas Pharma Inc (ALPMY.PK)

Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive bladder agent Vesicare, Protopic ointment for atopic dermatitis, Harnal for prostatic and urethral smooth muscle, and antimycotic agent Funguard, among others. It also provides pharmaceutical products for gastritis, chronic hepatitis C, irritable bowel syndrome, osteoporosis, hypertension, schizophrenia, rheumatoid arthritis, agrypnia, atopic dermatitis and other diseases. Advisors' Opinion:

• [By Henry Kawabe]

  Seattle Genetic is currently collaborating on 22 different ADC drug trials in various stages of testing with twelve different pharmaceutical companies, including nine with Genentech (RHHBY.OB), two with AbbVie (ABBV), two with Agensys (ALPMY.PK), and one with Pfizer (PFE). To date, these ADC collaborations have generated more than $225 million for Seattle Genetics and have the potential to generate more than $3.5 billion in milestone payments plus royalties.

Hot Defensive Companies To Invest In Right Now: Chindex International Inc.(CHDX)

Chindex International, Inc. engages in the provision of healthcare services; and sale of medical equipment, instrumentation, and products. The company operates in two segments, Healthcare Services and Medical Products. The Healthcare Services segment owns and operates the United Family Healthcare network of private hospitals and clinics in the Beijing, Shanghai, and Guangzhou markets. This segment also operates a managed clinic in the city of Wuxi, south of Shanghai. It offers a range of family healthcare services, including 24/7 emergency rooms, intensive care units, and neonatal intensive care units, operating rooms, clinical laboratory, radiology, and blood banking services for men, women, and children. The Medical Products segment markets, distributes, and sells medical capital equipment, instrumentation, and other medical products for use in hospitals in China and Hong Kong. It offers diagnostic color ultrasound imaging devices, robotic surgical systems and instrument ation, mammography and breast biopsy devices, and lasers for cosmetic surgery. This segment sells its products through its direct sales force. The company was founded in 1981 and is based in Bethesda, Maryland.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Leading and Lagging Sectors
  Tuesday morning, the healthcare sector proved to be a source of strength for the market. Healthcare stocks surged 1% in today's trading. Leading the sector was strength from Forest Laboratories (NYSE: FRX) and Chindex International (NASDAQ: CHDX) on acquisition news.

• [By Jake L'Ecuyer]

  Leading the sector was strength from Forest Laboratories (NYSE: FRX) and Chindex International (NASDAQ: CHDX) on acquisition news. In trading on Tuesday, non-cyclical consumer goods & services shares were relative laggards, down on the day by 0.2%.

• [By Anna Prior]

  Among the companies with shares expected to actively trade in Monday’s session are Citigroup Inc.(C), JA Solar Holdings(JASO) Co and Chindex International Inc.(CHDX)

Hot Defensive Companies To Invest In Right Now: American Assets Trust Inc (AAT)

American Assets Trust, Inc. is a full-service vertically integrated and self-administered real estate investment trust (REIT). The Company owns, operates, acquires and develops retail, office, multi-family and mixed-use properties primarily in Southern California, Northern California, Oregon and Hawaii. The Company operates in four business segments: retail, office, multi-family and mixed-use. As of December 31, 2011, its portfolio consisted of 10 retail shopping centers; six office properties; a mixed-use property consisting of a 369-room all-suite hotel and a retail shopping center, and four multi-family properties. As of December 31, 2011, it owned land at five of its properties that the Company classified as held for development. On January 24, 2012, it acquired One Beach Street, consisting of approximately 97,000 rentable square feet in a renovated office building located along the Embarcadero in San Francisco�� North Waterfront District. On August 30, 2011, it sold Valencia Corporate Center.

On March 11, 2011, the Company acquired First & Main, an approximately 361,000 square foot, 16-story, office building located at 100 SW Main Street, in Portland, Oregon. On July 1, 2011, it acquired the Lloyd District Portfolio, consisting of approximately 610,000 rentable square feet on more than 16 acres located in the Lloyd District of Portland, Oregon. On September 20, 2011, it acquired the Solana Beach-Highway 101 property, consisting of approximately 1.7 acres located in Solana Beach, California. On December 14, 2011, it acquired an additional 0.2 acres adjacent to such location.

The Company is the sole general partner of American Assets Trust, L.P., a Maryland limited partnership (the Operating Partnership). The Company, as the sole general partner has control of its Operating Partnership and owned 67.8% of its Operating Partnership as of December 31, 2011. At December 31, 2011, its operating portfolio had approximately 705 leases with office and retail tenants, of which s! even expired on December 31, 2011 and 15 had not yet commenced. Its residential properties had approximately 753 leases with residential tenants at December 31, 2011, excluding Santa Fe Park RV Resort. The retail portion of its mixed-use property had approximately 64 leases with retailers.

Retail

The products for its retail segment primarily include rental of retail space and other tenant services, including tenant reimbursements, parking and storage space rental. The Company�� retail properties include Carmel Country Plaza, South Bay Marketplace, Rancho Carmel Plaza, Lomas Santa Fe Plaza, Solana Beach Towne Centre, The Shops at Kalakaua, Waikele Center and Alamo Quarry Market. Its retail portfolio included 10 properties with a total of approximately three million rentable square feet available for lease as of December 31, 2011. As of December 31, 2011, these properties were 95% leased. During the year ended December 31, 2011, it signed 69 retail leases for 247,560 square feet. During 2011, the retail segment contributed 41.2%, of its total revenue.

Office

The products for its office segment primarily include rental of office space and other tenant services, including tenant reimbursements, parking and storage space rental. The Company�� office properties include Torrey Reserve, Solana Beach Corporate Centre, 160 King Street and The Landmark at One Market. Its office portfolio included six properties with a total of approximately 2.2 million rentable square feet available for lease as of December 31, 2011. As of December 31, 2011, these properties were 94.4% leased. During 2011, it signed 56 office leases for 233,213 square feet. During 2011, the office segment contributed 30.7% of its total revenue.

Multi-family

The products for its multi-family segment include rental of apartments and other tenant services. Its multi-family portfolio included three apartment properties, as well as an RV resort, with a total of 922 units! (includi! ng 122 RV spaces) available for lease as of December 31, 2011. As of December 31, 2011, these properties were 91.8% leased. Its multi-family leases, other than at its RV Resort, generally have lease terms ranging from 7 to 15 months, with a majority having 12-month lease terms. The Company�� multi-family properties include Loma Palisades, Imperial Beach Gardens, Mariner�� Point and Santa Fe Park RV Resort.

Mixed-Use Property

The products of its mixed-use segment include rental of retail space and other tenant services, including tenant reimbursements, parking and storage space rental and operation of a 369-room all-suite hotel. Waikiki Beach Walk Retail and Hotel is a mixed-use property. Its mixed-use property consists of 97,000 rentable square feet of retail space and a 369-room all-suite hotel. Revenue from the mixed-use property consists of revenue earned from retail leases, and revenue earned from the hotel, which consists of room revenue, food and beverage services, parking and other guest services. As of December 31, 2011, the retail portion of the property was 99.2% leased, and during 2011, the hotel had an average occupancy of 88.4%.

Advisors' Opinion:

• [By James E. Brumley]

  You can put American Assets Trust, Inc. (NYSE:AAT) and Park Electrochemical Corp. (NYSE:PKE) on your watchlist, if not in your portfolio. These two stocks are the best of the best among names you've probably not heard of. Just because you haven't heard of a stock, however, doesn't mean it can't dole out nice rewards. Indeed, I'm convinced the more obscure names like PKE and AAT are the market's best trading opportunities specifically because they're picks off the beaten path - the trades aren't crowded yet.

• [By Life Sciences Report]

  AF: Kamada Ltd. (KMDA) is a relatively unknown Israeli company that is doing very well. It is listed on the Tel Aviv Stock Exchange and the NASDAQ. It has an intravenous form of a drug for alpha-1 antitrypsin (AAT) deficiency, which causes lung and liver disease, that is partnered with Baxter International Inc. (BAX).